US Biopharma ‘Consortium’ Promises Array Of Coronavirus Remedies
Executive Summary
Trump Administration officials pledge support for basic science and expedited regulatory review while emphasizing the benefits that could be offered by drugs in the near term until a vaccine is developed.
You may also be interested in...
Trump’s Rhetorical Pivot On Pharma: The Hucksterism Is Still A Threat
It is nice for pharma CEOs to be called ‘brilliant’ by a President who once said they are ‘getting away with murder.’ But the ‘new’ Trump rhetoric still has major pitfalls for industry – including a fundamental risk of undermining regulatory standards.
Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
White House Hypes Chloroquine, A Drug Currently In Shortage, As Coronavirus Treatment Hope
Efficacy trials are under way and one supplier already has said it would restart production to meet the anticipated demand.